ES2070492T3 - Reactividad inmunitaria para oncogenes expresados activos para diagnostico y tratamiento de estados malignos. - Google Patents

Reactividad inmunitaria para oncogenes expresados activos para diagnostico y tratamiento de estados malignos.

Info

Publication number
ES2070492T3
ES2070492T3 ES91903946T ES91903946T ES2070492T3 ES 2070492 T3 ES2070492 T3 ES 2070492T3 ES 91903946 T ES91903946 T ES 91903946T ES 91903946 T ES91903946 T ES 91903946T ES 2070492 T3 ES2070492 T3 ES 2070492T3
Authority
ES
Spain
Prior art keywords
diagnosis
treatment
oncogens
expressive
evil
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES91903946T
Other languages
English (en)
Inventor
Martin A Cheever
David J Peace
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Washington Research Foundation
Original Assignee
Washington Research Foundation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Washington Research Foundation filed Critical Washington Research Foundation
Application granted granted Critical
Publication of ES2070492T3 publication Critical patent/ES2070492T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/82—Translation products from oncogenes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/461—Cellular immunotherapy characterised by the cell type used
    • A61K39/4611—T-cells, e.g. tumor infiltrating lymphocytes [TIL], lymphokine-activated killer cells [LAK] or regulatory T cells [Treg]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
    • A61K39/4643—Vertebrate antigens
    • A61K39/4644—Cancer antigens
    • A61K39/464454—Enzymes
    • A61K39/464464—GTPases, e.g. Ras or Rho
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4746—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used p53
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5091—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing the pathological state of an organism
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/5748—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving oncogenic proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
    • A61K2239/31—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterized by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
    • A61K2239/38—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S436/00—Chemistry: analytical and immunological testing
    • Y10S436/811—Test for named disease, body condition or organ function
    • Y10S436/813—Cancer

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Oncology (AREA)
  • Biochemistry (AREA)
  • Cell Biology (AREA)
  • Microbiology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biotechnology (AREA)
  • Physics & Mathematics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Food Science & Technology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Analytical Chemistry (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Zoology (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Toxicology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Mycology (AREA)
  • Hospice & Palliative Care (AREA)
  • Physiology (AREA)
  • Tropical Medicine & Parasitology (AREA)

Abstract

SE DESCRIBEN METODOS PARA LA DETECCION, CONTROL Y TRATAMIENTO DE MALIGNIDADES. LA DETECCION DE LA PROLIFERACION DE CELULAS T EN RESPUESTA A EXPOSICION IN VITRO A UNA PRODUCTO EXPRIMIDO DE LA PROTEINA DE UN ONCOGENO ACTIVADO O GEN RELACIONADO CON EL CANCER ASOCIADO CON UNA MALIGNIDAD, O LA DETECCION DE INMUNOCOMPLEJOS FORMADOS ENTRE EL PRODUCTO EXPRIMIDO DE LA PROTEINA Y ANTICUERPOS EN FLUIDO CORPORAL, PERMITE LA DIAGNOSIS DE LA PRESENCIA DE UNA MALIGNIDAD. ESTE INVENTO MUESTRA TAMBIEN METODOS Y COMPOSICIONES PARA TRATAR UNA MALIGNIDAD.
ES91903946T 1990-01-26 1991-01-24 Reactividad inmunitaria para oncogenes expresados activos para diagnostico y tratamiento de estados malignos. Expired - Lifetime ES2070492T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US47064590A 1990-01-26 1990-01-26

Publications (1)

Publication Number Publication Date
ES2070492T3 true ES2070492T3 (es) 1995-06-01

Family

ID=23868429

Family Applications (2)

Application Number Title Priority Date Filing Date
ES94109426T Expired - Lifetime ES2134294T3 (es) 1990-01-26 1991-01-24 Reactividad inmune para oncogenes expresados activos para la diagnosis y el tratamiento de tumores malignos.
ES91903946T Expired - Lifetime ES2070492T3 (es) 1990-01-26 1991-01-24 Reactividad inmunitaria para oncogenes expresados activos para diagnostico y tratamiento de estados malignos.

Family Applications Before (1)

Application Number Title Priority Date Filing Date
ES94109426T Expired - Lifetime ES2134294T3 (es) 1990-01-26 1991-01-24 Reactividad inmune para oncogenes expresados activos para la diagnosis y el tratamiento de tumores malignos.

Country Status (10)

Country Link
US (5) US5320947A (es)
EP (2) EP0513161B1 (es)
JP (3) JP2552047B2 (es)
AT (2) ATE120860T1 (es)
AU (1) AU639311B2 (es)
CA (1) CA2074720C (es)
DE (2) DE69108716T2 (es)
DK (1) DK0617124T3 (es)
ES (2) ES2134294T3 (es)
WO (1) WO1991011719A1 (es)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2011099A1 (en) * 1989-04-19 1990-10-19 Stephen C. Wardlaw Determination of lymphocyte reactivity to specific antigens in blood
ATE120860T1 (de) * 1990-01-26 1995-04-15 Washington Res Found Immunreaktivität gegenüber exprimierten aktivierten oncogenen zur diagnose und behandlung von bösartigen geschwülsten.
GB9103974D0 (en) * 1991-02-26 1991-04-10 Norsk Hydro As Therapeutically useful peptides or peptide fragments
ATE178357T1 (de) * 1991-09-16 1999-04-15 Us Health Nachweismethoden für c-raf-1-genes.5
US5512473A (en) * 1993-01-29 1996-04-30 Brent; Roger Max-interacting proteins and related molecules and methods
US5801005A (en) * 1993-03-17 1998-09-01 University Of Washington Immune reactivity to HER-2/neu protein for diagnosis of malignancies in which the HER-2/neu oncogene is associated
US6953573B1 (en) 1993-03-17 2005-10-11 University Of Washington Compounds for eliciting or enhancing immune reactivity to HER-2/neu protein for prevention or treatment of malignancies in which the HER-2/neu oncogene is associated
US5869445A (en) * 1993-03-17 1999-02-09 University Of Washington Methods for eliciting or enhancing reactivity to HER-2/neu protein
US5419900A (en) 1993-05-19 1995-05-30 The United States Of America As Represented By The Department Of Of Health And Human Services Immunologic enhancement with intermittent interleukin-2 therapy
US6156316A (en) * 1995-05-08 2000-12-05 Sloan-Kettering Institute For Cancer Research Oncogene fusion protein peptide vaccines
US6942862B2 (en) * 1996-04-01 2005-09-13 University Of Washington Methods and compositions to generate immunity in humans against self tumor antigens by immunization with homologous foreign proteins
US6300081B1 (en) 1996-11-15 2001-10-09 Cornell Research Foundation, Inc. Activated ras interaction assay
DE19736691A1 (de) * 1997-08-22 1999-02-25 Michael Prof Dr Med Giesing Verfahren zur Charakterisierung und Identifizierung disseminierter und metastasierter Krebszellen
US6551780B1 (en) * 2000-03-31 2003-04-22 The Regents Of University Of California Detection of gene mutations or amplifications in melanocytic neoplasms
JP4658423B2 (ja) * 1999-08-03 2011-03-23 ザ オハイオ ステイト ユニバーシティ Ｈｅｒ−２タンパク質に対する免疫反応性を増強するためのポリペプチドおよびポリヌクレオチド
ATE553782T1 (de) * 1999-12-22 2012-05-15 Scripps Research Inst Pharmazeutische zusammensetzungen enthaltend src und / oder yes und deren verwendung
GB0007088D0 (en) * 2000-03-23 2000-05-17 Torsana A S Detection of immunological memory determining the position of loci of pathologyand therapeutic t-cell conjugates
US6772026B2 (en) 2000-04-05 2004-08-03 Therics, Inc. System and method for rapidly customizing design, manufacture and/or selection of biomedical devices
US20030119079A1 (en) * 2001-09-19 2003-06-26 The Regents Of The University Of Michigan Detection and treatment of cancers of the breast
US20040076978A1 (en) * 2001-11-14 2004-04-22 Catherine Verfaillie Method to identify genes associated with chronic myelogenous leukemia
US7794657B2 (en) * 2003-06-03 2010-09-14 Cantimer, Inc. Phase change sensor
CN101193905B (zh) 2005-02-11 2014-06-25 纪念斯隆-凯特林癌症中心 用于检测抗药egfr突变体的方法和组合物
JP5222134B2 (ja) * 2005-06-15 2013-06-26 ザ オハイオ ステート ユニバーシティー リサーチ ファウンデーション Ｈｅｒ−２ペプチド
EP1973946B1 (en) * 2006-01-20 2015-03-25 Cell Signaling Technology, Inc. Translocation and mutant ros kinase in human non-small cell lung carcinoma
US8383799B2 (en) 2006-01-20 2013-02-26 Cell Signaling Technology, Inc. Translocation and mutant ROS kinase in human non-small cell lung carcinoma
US9732131B2 (en) 2006-02-27 2017-08-15 Calviri, Inc. Identification and use of novopeptides for the treatment of cancer
EP1994181A4 (en) * 2006-02-27 2010-05-19 Univ Arizona IDENTIFICATION AND USE OF NOVOPEPTIDES FOR THE TREATMENT OF CANCER
US8171270B2 (en) * 2006-12-29 2012-05-01 Intel Corporation Asynchronous control transfer
US20100234283A1 (en) 2009-02-04 2010-09-16 The Ohio State University Research Foundation Immunogenic epitopes, peptidomimetics, and anti-peptide antibodies, and methods of their use
US20200276285A1 (en) 2017-06-02 2020-09-03 Arizona Board Of Regents On Behalf Of Arizona State University A method to create personalized cancer vaccines
US12025615B2 (en) 2017-09-15 2024-07-02 Arizona Board Of Regents On Behalf Of Arizona State University Methods of classifying response to immunotherapy for cancer
EP4038222A4 (en) 2019-10-02 2023-10-18 Arizona Board of Regents on behalf of Arizona State University METHODS AND COMPOSITIONS FOR IDENTIFYING NEOANTIGENS FOR USE IN THE TREATMENT AND PREVENTION OF CANCER

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4411990A (en) * 1979-06-13 1983-10-25 University Patents, Inc. Primary bioassay of human tumor stem cells
US4376110A (en) * 1980-08-04 1983-03-08 Hybritech, Incorporated Immunometric assays using monoclonal antibodies
US4643968A (en) * 1981-01-29 1987-02-17 Massachusetts Institute Of Technology Process for determining metabolism and growth of cells under various conditions
CA1219232A (en) * 1983-08-17 1987-03-17 Richard A. Lerner Polypeptide-induced monoclonal receptors to protein ligands
JPS62103573A (ja) * 1985-08-21 1987-05-14 オンコジ−ン・サイエンス・インコ−ポレ−テツド Ｒａｓがコ−ドしているタンパク質の検出用イムノアツセイ
JPH076982B2 (ja) * 1985-11-06 1995-01-30 株式会社ニチレイ 抗 体
EP0269677A4 (en) * 1986-05-06 1990-03-08 Univ California ANALYZES AND ANTIBODIES OF N - i PROTEINS (myc).
US4820631A (en) * 1986-07-30 1989-04-11 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Deletion mutants and monoclonal antibodies against ras proteins
US4861589A (en) * 1987-03-23 1989-08-29 Trustees Of Boston University Method for therapeutically treating abnormal cells expressing a major histocompatibility complex class II antigen using cytolytic inducer T4 cells
US4957859A (en) * 1988-02-16 1990-09-18 Hoffmann-La Roche Inc. Antibodies for transforming ras protein
ES2106033T3 (es) * 1989-05-19 1997-11-01 Genentech Inc Dominio extracelular de her2.
ATE120860T1 (de) * 1990-01-26 1995-04-15 Washington Res Found Immunreaktivität gegenüber exprimierten aktivierten oncogenen zur diagnose und behandlung von bösartigen geschwülsten.

Also Published As

Publication number Publication date
AU7329991A (en) 1991-08-21
EP0513161B1 (en) 1995-04-05
JPH05503996A (ja) 1993-06-24
DE69131255D1 (de) 1999-06-24
US20040235070A1 (en) 2004-11-25
US5320947A (en) 1994-06-14
DK0617124T3 (da) 1999-12-06
WO1991011719A1 (en) 1991-08-08
ATE120860T1 (de) 1995-04-15
DE69108716T2 (de) 1995-08-17
US20030083229A1 (en) 2003-05-01
JP2552047B2 (ja) 1996-11-06
US5601989A (en) 1997-02-11
US5773230A (en) 1998-06-30
DE69131255T2 (de) 1999-12-16
JPH1169976A (ja) 1999-03-16
CA2074720C (en) 2002-07-23
EP0513161A1 (en) 1992-11-19
ATE180276T1 (de) 1999-06-15
DE69108716D1 (de) 1995-05-11
AU639311B2 (en) 1993-07-22
EP0617124B1 (en) 1999-05-19
JPH08275774A (ja) 1996-10-22
CA2074720A1 (en) 1991-07-27
ES2134294T3 (es) 1999-10-01
EP0617124A1 (en) 1994-09-28

Similar Documents

Publication Publication Date Title
ES2070492T3 (es) Reactividad inmunitaria para oncogenes expresados activos para diagnostico y tratamiento de estados malignos.
WO2020231882A3 (en) Modified pluripotent cells
EP1129718A3 (en) Therapeutic uses of bactericidal/permeability increasing protein products
NL7612210A (nl) Permanente magneet voor het implanteren in een lichaamsdeel, in het bijzonder in de oogleden.
ES324545A1 (es) Perfeccionamientos en la fabricacion de piezas para la cirugia y la medicina dental.
SE402213B (sv) Konstgjord stoma for perkutan genomforing av i kroppen inopererade, langstreckta implantat
GB8922026D0 (en) Novel anti-viral and cytotoxic agent
ES2128411T3 (es) Inhalador de polvo con soportes de polvo con microestructuras regulares.
ATE375362T1 (de) Von cyclophilin b abstammende tumorantigen- peptide
NO304580B1 (no) Doseringsform for medikamentavgivelse med tidsvarierende m°nstre
FI952607A0 (fi) Farmakologisesti aktiiviset pyridiinijohdannaiset ja menetelmät niiden valmistamiseksi
ES2056180T3 (es) Nuevos derivados de 2'-halometiliden, 2'-eteniliden y 2'-etinil citidina.
ES2093050T3 (es) Material implantable de deposito de sustancias activas.
SE9101815D0 (sv) Behandling av sjukdom foerbunden med hiv-infektioner
AU7866201A (en) NK cells activating receptors and their therapeutic and diagnostic uses
ME00578A (en) Use of gastrointestinal lipase inhibitors
NL7606183A (nl) Lens als vervanging voor de uit het oog van een levend wezen operatief verwijderen natuurlijke lens.
RS50148B (sr) Upotreba docetaksela za lečenje hepatoćelijskog karcinoma
DK0841912T3 (da) 2-Aminocarbonyl-1,2-bis-(methylsulfonyl)-1-(substituerede)-hydraziner med antitumor-virkning
IT1249047B (it) Composizione farmaceutica per il trattamento della cataratta
PT768886E (pt) Efeitos de revestimento endotelial e tratamento de desordens vasospasticas
ITMI920955A1 (it) Idrogeli di tipo polietereammidoamminico come materiali eparinizzabili
TR200401810T4 (tr) Kısırlık tedavisinde fsh'ın kullanılması
DE69626544D1 (de) Arzneistoffe
ATE131729T1 (de) 3,5-diiod-l-thyronin zur tsh-suppression und behandlung von struma

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 513161

Country of ref document: ES